There are no products in your shopping cart.
| 0 Items | $0.00 |
News
Alzheimer’s Association International Conference, July 28 – August 1, 2024, Philadelphia, Pennsylvania
Cognistat will be exhibiting, in person, as a solution provider at the AAIC 2024 (Alzheimer’s Association International Conference), July 28 – August 1, 2024, at the Pennsylvania Convention Center, Philadelphia, Pennsylvania. Come join us at Booth # 1037.
The Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that'll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. For more information, please visit https://aaic.alz.org/
American Occupational Therapy Association, March 21st - 23rd , 2024, Orlando, Florida
Cognistat will be exhibiting as a Solution Provider at the annual American Occupational Therapy Association (AOTA 2024), March 21st - 23rd, 2024, in Orlando, Florida. Come join us at Booth #734.
The American Occupational Therapy Association (AOTA) is the national professional association established in 1917 to represent the interests and concerns of occupational therapy practitioners and students of occupational therapy and to improve the quality of occupational therapy services. For more information, please visit www.aota.org.
National Academy of Neuropsychology, Annual Conference, Oct 25th - 28th, 2023, Philadelphia
Cognistat will be exhibiting at the National Academy of Neuropsychology (NAN) annual conference October 25-28, 2023, in Philadelphia, Pennsylvania. Come join us at Booth #502 to learn more about how Cognistat can be a valuable addition to your current cognitive assessment battery.
NAN Mission & Objectives
The mission of the National Academy of Neuropsychology is to advance neuropsychology as a science and health profession, to promote human welfare, and to generate and disseminate knowledge of brain-behavior relationships.
In order to fulfill its mission, the National Academy of Neuropsychology has established the following objectives:
- to provide information and support to the membership and the profession to enhance neuropsychological assessment, treatment, and consultation services;
- to disseminate neuropsychological knowledge through meetings, professional contacts, publications, reports, the Internet, and other forms of media;
- to promote research to improve knowledge of brain-behavior relationships and
- to improve the efficacy of outcomes in neuropsychological evaluations and interventions; (VALUE/GOAL= Research) to encourage membership to aspire to the profession's highest ethical standards;
- to promote understanding of cultural and individual diversity as it applies to the study and practice of neuropsychology;
- to promote the field of neuropsychology as a career choice among students, thus supporting student participation in the Academy's activities;
- to provide education to the public that fosters healthy behavior and the prevention of neurological illness and injury;
- to advocate in various forums on behalf of the profession, health consumers, and the promotion of neuropsychological health.
American Geriatrics Society, 2023 Annual Scientific Meeting, May 4-6, in Long Beach, CA
COGNISTAT will be exhibiting at the American Geriatrics Society, 2023 Annual Scientific Meeting, May 4-6 in Long Beach, CA . Come join us at Booth #212 to learn more about how Cognistat can be a valuable addition to your current cognitive assessment battery.
About The AGS
Founded in 1942, the American Geriatrics Society (AGS) is a nationwide, not-for-profit society of geriatrics healthcare professionals dedicated to improving the health, independence, and quality of life of older people. Our 6,000+ members include geriatricians, geriatrics nurse practitioners, social workers, family practitioners, physician assistants, pharmacists, and internists who are pioneers in advanced-illness care for older individuals, with a focus on championing interprofessional teams, eliciting personal care goals, and treating older people as whole persons.
The Society provides leadership to healthcare professionals, policymakers, and the public by implementing and advocating for programs in patient care, research, professional and public education, and public policy.
For more information, visit AmericanGeriatrics.org.
42nd Annual Conference of the National Academy of Neuropsychology (NAN), October 12-15, 2022
Cognistat will be exhibiting, in person, at the National Academy of Neuropsychology (NAN) annual conference, October 12-15, 2022, in Denver, Colorado. Come join us at Booth #203 to learn more about how Cognistat can be a valuable addition to your current cognitive assessment battery.
NAN Mission & Objectives
The mission of the National Academy of Neuropsychology is to advance neuropsychology as a science and health profession, to promote human welfare, and to generate and disseminate knowledge of brain-behavior relationships.
In order to fulfill its mission, the National Academy of Neuropsychology has established the following objectives:
- to provide information and support to the membership and the profession to enhance neuropsychological assessment, treatment, and consultation services; (VALUE/GOAL= Professional Development)
- to disseminate neuropsychological knowledge through meetings, professional contacts, publications, reports, the Internet, and other forms of media; (VALUE/GOAL= Education & Training)
- to promote research to improve knowledge of brain-behavior relationships and
- to improve the efficacy of outcomes in neuropsychological evaluations and interventions; (VALUE/GOAL= Research) to encourage membership to aspire to the profession's highest ethical standards; (VALUE/GOAL= Ethics)
- to promote understanding of cultural and individual diversity as it applies to the study and practice of neuropsychology; (VALUE/GOAL= Diversity)
- to promote the field of neuropsychology as a career choice among students, thus supporting student participation in the Academy's activities; (VALUE/GOAL=Students)
- to provide education to the public that fosters healthy behavior and the prevention of neurological illness and injury; (VALUE/GOAL=Public Education)
- to advocate in various forums on behalf of the profession, health consumers, and the promotion of neuropsychological health. (VALUE/GOAL= Advocacy)
For more information, please visit www.nanonline.org
Annual Meeting of the American Academy of Clinical Neuropsycholgy, June 23 - 25, 2022, Minneapolis
Cognistat will be exhibiting as a solution provider at the American Academy of Clinical Neuropsycholgy Meeting, June 23 - 25, 2022, in Minneapolis, Minnesota. Come join us to learn more about the Cognistat Assessment System.
The American Academy of Clinical Neuropsychology aims to achieve its missions through its dedication to the following purposes:
- To promote board certification by the American Board of Clinical Neuropsychology (ABCN) as the standard for competence in the practice of Clinical Neuropsychology.
- Support for those principles, policies and practices that seek the attainment of the best in clinical neuropsychological patient care.
- The pursuit of excellence in psychological education, especially as it concerns the clinical neuropsychological sciences.
- The pursuit of high standards in the practice of clinical neuropsychology and support of the credentialing activities of the American Board of Clinical Neuropsychology.
- Support for the quest of scientific knowledge by support for research in neuropsychology and related fields.
- The communication of scientific and scholarly information through continuing education, scientific meetings, and publications.
- Provision for communication with other groups and representation for clinical neuropsychological opinion to best achieve and preserve the purposes of the Academy.
For more information, please visit https://theaacn.org/
Annual Meeting of the Alzheimer's Association International, July 31st to August 4th, 2022, San Diego
Cognistat will be exhibiting as a solution provider at the 2022 Alzheimer’s Association International Conference, July 31 – August 4, 2022, in San Diego, California. Please join us at Booth #312.
The Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that'll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease.
For more information, please visit https://aaic.alz.org/
Annual Scientific Meeting of the American Geriatrics Society (AGS), May 12-14, 2022, Orlando
Cognistat will be participating as a solution provider at the 2022 Annual Scientific Meeting of the American Geriatrics Society (AGS), May 12-14, in Orlando, Florida. Come join us at Booth #302.
Founded in 1942, the American Geriatrics Society (AGS) is a nationwide, not-for-profit society of geriatrics healthcare professionals dedicated to improving the health, independence, and quality of life of older people. Our 6,000+ members include geriatricians, geriatrics nurse-practitioners, social workers, family practitioners, physician assistants, pharmacists, and internists who are pioneers in advanced-illness care for older individuals, with a focus on championing interprofessional teams, eliciting personal care goals, and treating older people as whole persons. AGS advocates for policies and programs that support the health, independence, and quality of life of all of us as we age.
The Society provides leadership to healthcare professionals, policymakers, and the public by implementing and advocating for programs in patient care, research, professional and public education, and public policy. For more information, visit AmericanGeriatrics.org.
41st Annual Conference of the National Academy of Neuropsychology (virtual edition), December 9 - 10, 2021.
Cognistat will be participating as a solution provider and sponsor at the 41st National Academy of Neuropsychology (NAN) annual conference (virtual edition), December 9-10, 2021.
The National Academy of Neuropsychology (NAN) is a non-profit professional membership association for experts in the assessment and treatment of brain injuries and disorders. NAN members work in the most prestigious universities, hospitals and private practices throughout the world and are at the forefront of cutting-edge research and rehabilitation in the field of brain behavior relationships.
www.nanonline.org
HEALTHTAC (Senior Living) Virtual Connect 2021, March 23rd, 2021
Cognistat was proud to be a Vendor Partner at the 2021 HealthTAC virtual conference for Senior Living on March 23rd.
Cognistat CEO, Parsa Famili, was on a panel discussion where some interesting and insightful points were brought up. Successful pioneers of practical and progressive strategies discussed key challenges, interests, and relevant market developments. Educational sessions were designed to help drive high-impact innovation and transformation in order to help tackle emerging issues facing the healthcare industry.
American Geriatrics Society Annual Conference, May 7 - 8, 2020, Long Beach, California
Cognistat will be exhibiting at the 2020 American Geriatrics Society (AGS) annual conference on May 7-8 , at the Long Beach Convention and Entertainment Center, Long Beach, California. Please visit us at booth #205. For more information about the AGS please visit:
https://meeting.americangeriatrics.org/
Founded in 1942, the American Geriatrics Society (AGS) is a nationwide, not-for-profit society of geriatrics healthcare professionals dedicated to improving the health, independence, and quality of life of older people. With nearly 6,000 members the AGS includes geriatricians, geriatric nurses, social workers, family practitioners, physician assistants, pharmacists, and internists. The Society provides leadership to healthcare professionals, policymakers, and the public by implementing and advocating for programs in patient care, research, professional and public education, and public policy.
39th National Academy of Neuropsychology Annual Convention, Nov 13 - 16, 2019, San Diego, California
Cognistat will be exhibiting at the 39th National Academy of Neuropsychology Annual Convention on Nov 13 - 16, 2019 at the Hilton San Diego Bayfront, San Diego, California. The National Academy of Neuropsychology is a professional society that includes clinicians, scientist-practitioners, and researchers interested in neuropsychology. Its mission is to advance neuropsychology as a science and health profession, to promote human welfare, and to generate and disseminate knowledge of brain-behavior relationships.
Please visit us at Booth #208 for a demonstration of our Cognistat products.
For more information visit: https://www.emedevents.com/c/medical-conferences-2019/39th-annual-conference-of-national-academy-of-neuropsychology-nan
Organization for Human Brain Mapping, June 9-12, 2019, Rome, Italy
Cognistat will be exhibiting at the Organization for Human Brain Mapping on June 9 - 12, 2019, at the Auditorium Parco Della Musica in Rome, Italy. Please visit us at booth #33.
For more information visit: https://www.humanbrainmapping.org/i4a/pages/index.cfm?pageid=3920
The Organization for Human Brain Mapping is an international organization dedicated to advancing the understanding of the anatomical and functional organization of the human brain using neuroimaging.
InvestaCure Alzheimer's Solutions Conference, June 2 -3, 2019, Philadelphia
Cognistat will be exhibiting at the Alzheimer's Solutions Conference on June 2-3, 2019 at the University of the Sciences, Philadelphia, PA.
The conference will bring together scientists, physicians, patient families & funders in a collaborative effort to explore and advance innovations in the battle against Alzheimer's. For more information visit: https://www.investacure.com
American Occupational Therapy Association Conference, April 4 - 6, 2019, New Orleans.
Cognistat will be exhibiting at the Annual American Occupational Therapy Association Conference & Expo on April 4-6, 2019 in New Orleans, LA, at the Ernest N. Morial Convention Center. Please meet us at Booth 1620 for a demonstration of Cognistat and a chance to win free Cognistat products. This Annual Conference & Expo is the largest gathering of occupational therapy practitioners and students in the world. Approximately 10,000 occupational therapy practitioners and students are expected to attend from across the United States.
For more information visit: http://www.aota.org/Conference-Events/Annual-Conference.aspx
The American Occupational Therapy Association (AOTA) is the national professional association established in 1917 to represent the interests and concerns of occupational therapy practitioners and students of occupational therapy and to improve the quality of occupational therapy.
For more information please visit: http://www.aota.org/aboutaota.aspx
13th World Congress on Brain Injury, March 13 - 16, 2019, Toronto.
Cognistat will be exhibiting at the 13th World Congress on Brain Injury, March 13 - 16th 2019 at the Sheraton Centre Hotel, Toronto, Ontario, Canada.
Please visit us at Booth 428 for a demonstration of our Cognistat products.
For more information visit: www.ibia2019.org
Cognistat is pleased to announce its latest product, the Cognistat Arabic Assessment Tool, at the Arab Health Meeting in January 2017 in Dubai.
Cognistat is a rapid computerized cognitive assessment tool that quickly measures the five major domains of cognitive functioning and it is used to screen and quantify neuropsychological problems across a broad spectrum of patients.
It is one of the most widely used cognitive screening tools in the world, with over 300 independent scientific articles describing its use in patients with traumatic brain injury (TBI), dementia, Mild Cognitive Impairment (MCI), stroke and substance abuse.
About the Researcher: Bazah Almubark is a qualified Occupational Therapist, Researcher and the translator of Cognistat Arabic Assessment Tool.
Ms. Almubark is currently completing her PhD in neuropsychology at the University of Plymouth, in the United Kingdom. Previously Ms. Almubark received a MSc. in Neurorehabilitation from Oxford Brooks University, UK. and a B.Sc. (Hons.) in Occupational Therapy from Brunel University, UK.
The author works in a rehabilitation hospital in Saudi Arabia, where she helps adults with neurological conditions to participate in meaningful daily living activities, assesses clients’ cognition and physical abilities, prescribes adaptive equipment, and assesses and modifies clients’ homes to enhance their safety and independence.
In addition, Ms. Almubark has completed a diploma in Occupational Therapy from Riyadh Al Karj Armed Forces Hospital - Centre for Studies and Training - Saudi Arabia, and previously worked as an Occupational Therapy Assistant.
Her current projects include cultural adaptation of a cognitive assessment tool - Cognistat - for the use in Arabic speaking population and the development of a long term memory test for Arabic patients with acquired brain injury.
Cognistat to introduce the newest additions “Cognistat Active Form & MCI Index” and “Cognistat Five” at the Annual Conference of the American Psychological Association in Denver, Colorado August 4-7, 2016.
The American Psychological Association is the largest scientific and professional organization representing psychology in the United States. APA is the world’s largest association of psychologists, with 150,000 researchers, educators, clinicians, consultants and students as its members.
· APA seeks to advance psychology as a science, a profession and as a means of promoting health, education and human welfare by:
· Encouraging the development and application of psychology in the broadest manner
· Promoting research in psychology, the improvement of research methods and conditions and the application of research findings
· Improving the qualifications and usefulness of psychologists by establishing high standards of ethics, conduct, education and achievement
· Increasing and disseminating psychological knowledge through meetings, professional contacts, reports, papers, discussions and publications
Cognistat Recognized by Hon. Dr. Eric Hoskins, Minister of Health & Long Term Care, Ontario Canada at Arab Health 2016
Cognistat has been recognized as the Global Leader in computerized rapid assessment tools for the diagnosis of Alzheimer’s and dementia by Dr. Eric Hoskins, Minister of Health and Long Term Care, Ontario, Canada.
Arab Health was Novatek’s first stopping point of 2016! The Middle East is very important to Novatek with many client installations in and around the region. Together with Cognistat, Novatek’s medical data systems company, we were proud to be exhibiting among the many other great exhibitors at the Canada Pavilion. Arab Health provides the largest gathering of healthcare experts in the Middle East, maybe even the world and it is the perfect fit for Novatek and Cognistat to share our innovative technologies and most importantly learn from others about what is happening in the Gulf region and the latest in healthcare and how we as an organization might gain from it. Establishing and building our relationships face to face at events like Arab Health is what Novatek strives for to ensure quality, compliance and support to our customers in this region. This year Novatek celebrates its 20th anniversary year and we look forward to traveling to all parts of the world meeting all kinds leaders from the healthcare industry representing Canada as one of their leaders in Software & Innovation in the healthcare and pharmaceutical industries!
Cognistat Supports the National Academy of Neuropsychology (NAN)
Cognistat is pleased to again support the NAN student program by donating Cognistat Assessment System tests for raffle at the 2014 National Academy of Neuropsychology (NAN) conference in Fajarto, Puerto Rico. This year Cognistat supported the NAN raffle by providing two $500 prizes. The raffle proceeds benefit NAN’s student programs.
Congratulations to this year’s winners; Dr. Phillip Lett and Dr. Karen J. Haskett. Each winner received a state-of-the-art Cognitive Assessment Tool allowing them to test and evaluate patients with cognitive impairment.
About Cognistat:
Cognistat is a rapid screening tool used to identify people suffering from mild, moderate and severe cognitive impairment. An ever-increasing number of middle-aged and elderly people with Mild Cognitive Impairment (MCI) or the onset of dementia remains undiagnosed due to a lack of simple and effective tools. With time, mild cognitive impairment that is left untreated becomes full-blown dementia.
Cognistat is a rapid cognitive-assessment tool used to screen and quantify neuropsychological problems across a broad spectrum of patients. Cognistat quickly assesses five major domains of cognitive functioning: orientation, attention, language, spatial skills; i.e. construction, memory, calculation and reasoning.
About NAN:
The National Academy of Neuropsychology is a non-profit professional membership association for experts in the assessment and treatment of brain injuries and disorders. NAN members work in the most prestigious universities, hospitals and private practices throughout the world and are at the forefront of cutting-edge research and rehabilitation in the field of brain behavior relationships.
Cognistat and the Sports Concussion Institute Announce Joint Venture - Cognistat Sport
April 22nd 2014
Cognistat and the Sports Concussion Institute and pleased to announce the formation of Cognistat Sport Joint Venture Inc., whose mission is to develop science-based software tools for the evaluation of concussion and associated injuries. Both companies are committed to providing new best-in-class tools for clinicans to triage, evaluate and manage concussion in athletes.
The Sports Concussion Institute (SCI) is a leading US provider of concussion assessment, diagnostic and clinical management services. SCI was founded in 2005 to provide state-of-the-art assessment, treatment and prevention services for athletes and other active persons of all ages playing high velocity sports. SCI provides specializied neurological and neurophysiological care to people with closed head injuries, acute and chronic pain, balance, memory and learning disorders. SCI has conducted more than 100,000 assessments of neurophysiological and vestibular functioning in athletes and continues to provide concussion eduction, prevention and clinical management services to middle schools, high school, universities and professional teams through the US.
Cognistat is a market leader in evaluating cognitive function in teenagers and adults. Its state-of-the-art computerized tools are available in 13 languages and are used worldwide. The original Cognistat Paper Test was introduced in 1979 and has become the most widely used screening tool by North American neuropsychologists and other healthcare practitioners. The cloud based Cognistat Assessment System and stand-alone Cognistat Active Form are computer assisted, clinician admistered versions of the orignal paper test and are designed to interface with electronic medical records, facilitate the monitoring of patients on repeat testing and provide a paper free environment. Cognistat Five is a five minute computer assisted test for evaluating the risk of dementia, delirium and mild congitive impairment in adults.
Dr. Tony Strickland, president of the new joint venture said, "SCI is honored, together with Cognistat, to launch this innovative partnership that will significantly enhance the health and safety of althletes playing high velocity sports. Additionaly, we are concerned about a subgroup of stand-alone, untried and/or untested software solutions used to evaluate concussion in althletes and to make "return to competition" decisions. We strongly believe that clincians must play a key role in concussion evaluation and our goal is to design best-in-class software-based tools that facilitate their specialized work. Our two companies are well suited to bring a new level of excellence, combined with pragmatism and convenience, to concussion evaluation."
We invite you to visit us at Booth 1 at the 8th Annual National Summit on Sports Concussion, May 2nd, 2014 at the LAX Marriott, Los Angeles.
For further information please contact:
Jay Paik, MPH, JD, Vice President of Business Operations and General Counsel.
E-mail jay.paik@concussiontreatment.com Phone +1 (310) 643 9595
Cognistat Announces New Five Minute Test for Dementia
July 29th 2013
Cognistat is pleased to announce the introduction of a new five minute test for risk assessment of Mild Cognitive Impairment (MCI) and dementia at the upcoming American Psychological Association Meeting, July 31st to August 4th, in Honolulu. Cognistat Five© is a cognitive screening tool for use by clinicians in determining the risk for cognitive decline in adults. The test incorporates a sophisticated clinical-based algorithm, the MCI Index, which is a graded seven point measure of cognitive decline. The MCI Index provides clinically useful cognitive information to physicians in the diagnosis of Mild Cognitive Impairment and dementia.
Cognistat Five© is the fifth product in Cognistat’s catalogue of cognitive assessment tools. The original Cognistat Paper test was introduced in 1979 and has become the most widely used screening tool used by North American neuropsychologists. It is available in eleven languages and is used worldwide. The Cognistat Assessment System and Cognistat Active Form are computer-assisted, clinician-administered versions of the original Paper test and are designed to interface with electronic medical records, facilitate the monitoring of patients on repeat testing and provide a paper-free environment.
Jonathan Mueller M.D., Chief Medical Officer, and one of the original developers of Cognistat, said, “Cognistat Five© offers primary care providers a rapid and cost effective way to screen for dementia and MCI by focusing on memory, constructions and orientation - the three ability areas most vulnerable to cognitive decline. This enables the test to be completed in normal healthy subjects in five minutes.” Parsa Famili, President and CEO of Cognistat said, ”Our goal is to provide cost-effective rapid computer-assisted screening tools for healthcare professionals. We have a substantial customer base and foresee a growing need for these products in aging populations throughout the world.”
Cognistat Inc. is a privately held company based in San Francisco and Montreal with sales offices in North and South America, Europe and Asia.
Please come and visit us at booth 602 at the American Psychological Association Meeting in Honolulu.
For further information please contact:
Mr. Parsa Famili, Cognistat Inc., +1 (514) 941 8893
Cognistat Announces MCI Index© Screening Tool for Dementia
May 28, 2013
Cognistat is pleased to announce the introduction of a new screening tool for risk assessment of Mild Cognitive Impairment (MCI) and Dementia. The Cognistat MCI Index© is a rapid cognitive screening tool for use by clinicians in determining the risk for cognitive decline in adults. The MCI Index is the first cognitive assessment instrument to incorporate a sophisticated clinical-based algorithm based on a patient’s performance on tests for Memory and Constructions and incorporating adjustments for age and education. The index provides a risk assessment that enables physicians to better diagnose Mild Cognitive Impairment in its earliest stages.
The Cognistat MCI Index is the fourth product in Cognistat’s catalogue of cognitive assessment tools. The original Cognistat Paper test was introduced in 1977 and has become the most widely used screening tool used by North American neuropsychologists. It is available in eleven languages and is used worldwide. The Cognistat Assessment System and Cognistat Active Form are computer-assisted versions of the original Paper test and are designed to interface with electronic medical records, facilitate the monitoring of patients on repeat testing and provide a paper-free environment. Both the Assessment System and the Active Form will now incorporate the MCI Index in their reports.
Dr. Ralph Kiernan, Chief Scientific Officer, and one of the original developers of Cognistat said, “We are pleased to be able to bring this product before the clinical community and research world. It offers the advantage of a sophisticated computer-based algorithm yet preserves the clinician-patient relationship.” Mr. Parsa Famili, President and CEO of Cognistat said “Our goal is to provide cost-effective rapid computer-assisted screening tools for healthcare professionals. We have a substantial customer base and foresee a growing need for these products in aging populations throughout the world.”
Cognistat Inc. is a privately held company based in San Francisco and Montreal with sales offices in North and South America, Europe and Asia.
For further information please contact:
Mr. Parsa Famili, Cognistat Inc., +1 (514) 941 8893